Fibronostics to Present LIVERFASt Data at DDW 2026
Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on […]
Resources
Fibronostics to Present at MASH-TAG 2026 Conference
Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer
Fibronostics Reaffirms Commitment to Quality with ISO 13485
At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we
Fibronostics at AASLD Liver Meeting 2025
Fibronostics is thrilled to announce its participation in the AASLD Liver Meeting 2025, the world’s leading conference dedicated to advancing
Fibronostics Acquires Stone Clinical Labs for MASH/MASLD Diagnostic Innovation
We’re excited to announce that Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced
Fibronostics Joins Experts in Liver Health at THASL 2025 Bangkok
On June 11-13, Fibronostics had the privilege of participating in the THASL 2025 Annual Conference, hosted by the Thai Association
LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
Fibronostics to Exhibit at THASL 2025 Annual Conference in Bangkok
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the
Fibronostics Achieves SOC 2 Compliance
Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and
Fibronostics is ISO27001:2022 Certified Yet Again in 2025
We did it again! Fibronostics is proud to announce that we have successfully renewed our ISO 27001:2022 certification for